157 related articles for article (PubMed ID: 15705616)
1. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
[TBL] [Abstract][Full Text] [Related]
6. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP
J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
Yamamoto A; Watanabe H; Sueki H; Nakanishi T; Yasuhara H; Iijima M
J Dermatol; 2007 Jul; 34(7):419-29. PubMed ID: 17584317
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
12. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.
Banerjee S; Zvelebil M; Furet P; Mueller-Vieira U; Evans DB; Dowsett M; Martin LA
Cancer Res; 2009 Jun; 69(11):4716-23. PubMed ID: 19435899
[TBL] [Abstract][Full Text] [Related]
13. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
[TBL] [Abstract][Full Text] [Related]
14. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Giles FJ; List AF; Carroll M; Cortes JE; Valickas J; Chen BL; Masson E; Jacques C; Laurent D; Albitar M; Feldman EJ; Roboz GJ
Leuk Res; 2007 Jul; 31(7):891-7. PubMed ID: 17560285
[TBL] [Abstract][Full Text] [Related]
17. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG
Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258.
Liu Y; Wen XM; Lui EL; Friedman SL; Cui W; Ho NP; Li L; Ye T; Fan ST; Zhang H
Lab Invest; 2009 Oct; 89(10):1152-60. PubMed ID: 19668241
[TBL] [Abstract][Full Text] [Related]
19. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D
Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389
[TBL] [Abstract][Full Text] [Related]
20. PTK/ZK (Novartis).
Drevs J
IDrugs; 2003 Aug; 6(8):787-94. PubMed ID: 12917775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
